CES Clinical Trial Article.pdf

Timothy H. Barclay

CES Clinical Trial Article.pdf

Research output: Contribution to journal › Article › peer-review

Abstract

<div class="line" id="line-5"> <br/></div><div class="line" id="line-97"> Background: Anxiety disorders are among the most prevalent mental disorders and are usually treated</div><div class="line" id="line-99"> with medication and/or psychotherapy. When anxiety disorders are accompanied with comorbid</div><div class="line" id="line-101"> depression, this further complicates the treatment process. Medication compliance is a common</div><div class="line" id="line-103"> problem due to adverse side effects and new and effective treatments that have minimal side effects</div><div class="line" id="line-105"> are needed for the treatment of anxiety and depression. This study used a randomized, double-blind,</div><div class="line" id="line-107"> sham controlled design to examine the effectiveness of CES as a treatment for anxiety disorders and</div><div class="line" id="line-109"> comorbid depression in a primary care setting. The study was registered at clinicaltrials.gov,</div><div class="line" id="line-111"> NCT01533415.</div><div class="line" id="line-113"> Methods: One hundred and &filig;fteen participants, age 18 years and over, with a primary diagnosis of an</div><div class="line" id="line-115"> anxiety disorder were enrolled from February 2012 to December 2012 The Hamilton Rating Scale for</div><div class="line" id="line-117"> Anxiety (HAM-A) and the Hamilton Depression Rating Scale17 (HAM-D17) were used for baseline and</div><div class="line" id="line-119"> outcome measures at weeks one, three, and &filig;ve. Response to treatment was de&filig;ned as a reduction of</div><div class="line" id="line-121"> Z50% or  more on these  measures.</div><div class="line" id="line-123"> Results: Analysis of covariance revealed a signi&filig;cant difference between the active CES group and</div><div class="line" id="line-125"> the sham CES group on anxiety (p ¼ 0.001, d ¼ 0.94) and on depression (p ¼ 0.001, d ¼ 0.78) from</div><div class="line" id="line-127"> baseline to endpoint of study in favor of the active CES  group.</div><div class="line" id="line-129"> Conclusions: CES signi&filig;cantly decreases anxiety and comorbid depression. Subjects reported no</div><div class="line" id="line-131"> adverse events during the study.</div><div class="line" id="line-133"> <br/></div><div class="line" id="line-136"> <br/></div><div class="line" id="line-139"> <br/></div><div class="line" id="line-142"> <br/></div><div class="line" id="line-145"> <br/></div><div class="line" id="line-148"> <br/></div><div class="line" id="line-151"> <br/></div><div class="line" id="line-154"> <br/></div><div class="line" id="line-157"> <br/></div><div class="line" id="line-160"> <br/></div><div class="line" id="line-163"> <br/></div><div class="line" id="line-166"> <br/></div><div class="line" id="line-169"> <br/></div><div class="line" id="line-172"> <br/></div><div class="line" id="line-174"> <br/></div>

Original language	American English
Journal	Journal of Affective Disorders
Volume	164
State	Published - Apr 11 2014

Keywords

anxiety
depression
cranial electrotherapy stimulation

Disciplines

Social and Behavioral Sciences
Psychology
Science and Technology Studies

Access to Document

CES Clinical Trial Article.pdfFinal published version, 649 KBLicense: Unspecified

Cite this

@article{ea0d334af2404b068cb77e9bb15fe4ed,

title = "CES Clinical Trial Article.pdf",

abstract = " Background: Anxiety disorders are among the most prevalent mental disorders and are usually treated with medication and/or psychotherapy. When anxiety disorders are accompanied with comorbid depression, this further complicates the treatment process. Medication compliance is a common problem due to adverse side effects and new and effective treatments that have minimal side effects are needed for the treatment of anxiety and depression. This study used a randomized, double-blind, sham controlled design to examine the effectiveness of CES as a treatment for anxiety disorders and comorbid depression in a primary care setting. The study was registered at clinicaltrials.gov, NCT01533415. Methods: One hundred and &filig;fteen participants, age 18 years and over, with a primary diagnosis of an anxiety disorder were enrolled from February 2012 to December 2012 The Hamilton Rating Scale for Anxiety (HAM-A) and the Hamilton Depression Rating Scale17 (HAM-D17) were used for baseline and outcome measures at weeks one, three, and &filig;ve. Response to treatment was de&filig;ned as a reduction of Z50% or  more on these  measures. Results: Analysis of covariance revealed a signi&filig;cant difference between the active CES group and the sham CES group on anxiety (p ¼ 0.001, d ¼ 0.94) and on depression (p ¼ 0.001, d ¼ 0.78) from baseline to endpoint of study in favor of the active CES  group. Conclusions: CES signi&filig;cantly decreases anxiety and comorbid depression. Subjects reported no adverse events during the study. ",

keywords = "anxiety, depression, cranial electrotherapy stimulation",

author = "Barclay, {Timothy H.}",

year = "2014",

month = apr,

day = "11",

language = "American English",

volume = "164",

journal = "Journal of Affective Disorders",

}

TY - JOUR

T1 - CES Clinical Trial Article.pdf

AU - Barclay, Timothy H.

PY - 2014/4/11

Y1 - 2014/4/11

N2 - Background: Anxiety disorders are among the most prevalent mental disorders and are usually treated with medication and/or psychotherapy. When anxiety disorders are accompanied with comorbid depression, this further complicates the treatment process. Medication compliance is a common problem due to adverse side effects and new and effective treatments that have minimal side effects are needed for the treatment of anxiety and depression. This study used a randomized, double-blind, sham controlled design to examine the effectiveness of CES as a treatment for anxiety disorders and comorbid depression in a primary care setting. The study was registered at clinicaltrials.gov, NCT01533415. Methods: One hundred and &filig;fteen participants, age 18 years and over, with a primary diagnosis of an anxiety disorder were enrolled from February 2012 to December 2012 The Hamilton Rating Scale for Anxiety (HAM-A) and the Hamilton Depression Rating Scale17 (HAM-D17) were used for baseline and outcome measures at weeks one, three, and &filig;ve. Response to treatment was de&filig;ned as a reduction of Z50% or  more on these  measures. Results: Analysis of covariance revealed a signi&filig;cant difference between the active CES group and the sham CES group on anxiety (p ¼ 0.001, d ¼ 0.94) and on depression (p ¼ 0.001, d ¼ 0.78) from baseline to endpoint of study in favor of the active CES  group. Conclusions: CES signi&filig;cantly decreases anxiety and comorbid depression. Subjects reported no adverse events during the study.

AB - Background: Anxiety disorders are among the most prevalent mental disorders and are usually treated with medication and/or psychotherapy. When anxiety disorders are accompanied with comorbid depression, this further complicates the treatment process. Medication compliance is a common problem due to adverse side effects and new and effective treatments that have minimal side effects are needed for the treatment of anxiety and depression. This study used a randomized, double-blind, sham controlled design to examine the effectiveness of CES as a treatment for anxiety disorders and comorbid depression in a primary care setting. The study was registered at clinicaltrials.gov, NCT01533415. Methods: One hundred and &filig;fteen participants, age 18 years and over, with a primary diagnosis of an anxiety disorder were enrolled from February 2012 to December 2012 The Hamilton Rating Scale for Anxiety (HAM-A) and the Hamilton Depression Rating Scale17 (HAM-D17) were used for baseline and outcome measures at weeks one, three, and &filig;ve. Response to treatment was de&filig;ned as a reduction of Z50% or  more on these  measures. Results: Analysis of covariance revealed a signi&filig;cant difference between the active CES group and the sham CES group on anxiety (p ¼ 0.001, d ¼ 0.94) and on depression (p ¼ 0.001, d ¼ 0.78) from baseline to endpoint of study in favor of the active CES  group. Conclusions: CES signi&filig;cantly decreases anxiety and comorbid depression. Subjects reported no adverse events during the study.

KW - anxiety

KW - depression

KW - cranial electrotherapy stimulation

M3 - Article

VL - 164

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

ER -